Prelude Therapeutics Inc Forecast, price target & analysts
Prelude Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Prelude Therapeutics Inc Classifications & Recommendation
Prelude Therapeutics Inc Price Target
| Target Price | $8.16 |
| Price | $3.88 |
| Potential |
110.58%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Prelude Therapeutics Inc 2027 .
The average Prelude Therapeutics Inc target price is $8.16.
This is
110.58%
register free of charge
$10.50
170.97%
register free of charge
$6.06
56.39%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Prelude Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Prelude Therapeutics Inc stock has an average upside potential 2027 of
110.58%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 12.14 | 67.45 |
| 73.43% | 455.63% | |
| EBITDA Margin | -847.28% | -172.92% |
| 57.00% | 79.59% | |
| Net Margin | -819.60% | -19.90% |
| 54.89% | 97.57% |
5 Analysts have issued a sales forecast Prelude Therapeutics Inc 2026 . The average Prelude Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Prelude Therapeutics Inc EBITDA forecast 2026. The average Prelude Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Prelude Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Prelude Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.29 | -0.17 |
| 23.21% | 86.82% | |
| P/E | negative | |
| EV/Sales | 2.33 |
5 Analysts have issued a Prelude Therapeutics Inc forecast for earnings per share. The average Prelude Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Prelude Therapeutics Inc...
Current Prelude Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Locked
➜
Locked
|
Locked | Sep 17 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 29 2026 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | May 04 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 27 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Mar 11 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 23 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Aug 18 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
JP Morgan:
Locked
➜
Locked
|
Sep 17 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 29 2026 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
May 04 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 27 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Mar 11 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 23 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Aug 18 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
